LBRI Institutional Biosafety Committee Meeting Minutes
2425 Ridgecrest Drive SE, Albuquerque, NM 87108
Special Meeting conducted via Zoom
September 24, 2025

Members in Attendance:
David Revelli (Chair)
Dale Mack (Vice Chair)
Debra Sharpe (BSO/RO)
Adriana Kajon
Nancy Davis
Carin Kelley
Ted Sanders
Rhonda Peyton (ARO)
Rene Matison
Annette Breer

Members Absent:
Richard Conn

Call to Order:
The meeting was called to order by the Chair Dr. David Revelli at 11:02 a.m. Dale Mack Vice Chair took lead for a few minutes.

I. Review of the August 12, 2025 Meeting Minutes will be reviewed during the October regularly scheduled meeting.

II. Old Business
None at this time.

III. New Business
FY26-002 Francisella tularensis Vaccine Lot Potency Assay in Mice, the study director gave a brief explanation of the protocol; Francisella tularensis is the bacterium that causes tularemia. F. tularensis is widespread in North America as well as in Europe and Asia. Transmission is often associated with ticks and mosquitoes, but the infection can also be acquired by ingesting contaminated food or water, via the respiratory route, bites from infected animals, or from direct contact with infected tissue. Tularemia is a serious and often fatal disease. Currently there is no licensed vaccine available for use in the United States. Tularemia infection in humans is highly burling and can be fatal thus unethical and not practical to test possible vaccines and therapeutics in humans. For this reason, medical countermeasures developed for inhalation tularemia need to be tested in animals and will fall under the FDA Animal Rule. Discussions ensued followed by a couple of questions, motion to pass (Kajon/Sanders) Revelli abstains, motion pass unanimously.

FY26-003_v3 Dose Range Finding and Efficacy Evaluation of Inhaled Antisense Oligonucleotide Targeting Muc5AC in Beagle Dogs, the study director gave a brief explanation of the protocol; Muco-obstructive lung diseases such as Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF), and Non-cystic Fibrosis Bronchiectasis (NCFB) are serious, progressive and sometimes life-threatening diseases characterized by excessive mucus production driven by the over-expression of the mucin protein, Muc5AC. Treatments to help regulate Muc5AC production are a potential path for therapeutic treatments of these conditions. The objective of this study is to define a minimal effective dose and dose-range of the test article needed to downregulate Muc5AC. The anticipated benefits including, reduced mucus burden and improved quality of life offer a promising therapeutic approach for millions affected by these chronic and potentially fatal conditions. The study will be conducted in 2 phases. Discussions ensued, Q&A for clarifications. Motion to pass with stipulations discussed minor modifications with details listed in protocol (Dale/Sanders) motion pass unanimously.

IV. Standing Reports
a. Security Reports
None to report
b. Laboratory Incidents
None to report
c. ABSL-3 Facility Inspection
None to report
d. Agents and Toxins Inventory
None to report

V. Other Business
None to report

Adjourn
There being no further business to conduct at this time, meeting adjourned at 11:49 a.m.

Next Meeting
The next regularly scheduled meeting of the LBRI Institutional Biosafety Committee is scheduled to occur on Tuesday, October 15, 2025 at 11:00 a.m.

Respectfully submitted,

David A. Revelli
Digitally signed by David A. Revelli
Date: 2025.12.03 14:42:44 -07'00'

David Revelli, Ph.D. Date
Chairman, IBC Committee

Annette Breer
Digitally signed by Annette Breer
Date: 2025.12.17 09:28:31 -07'00'

Annette Breer Date
Recording Secretary